Antivector and antitransgene host responses in gene therapy.
about
Production of adenovirus vectors and their use as a delivery system for influenza vaccines.Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells.Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccineProtection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.Regulatory T cells and immune tolerance to coagulation factor IX in the context of intramuscular AAV1 gene transfer.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersPersistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transferCurrent strategies and future directions for eluding adenoviral vector immunityAdenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosaEncapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunityProtective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccineAnti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responsesA Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosaGene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5.Adenovirus: the first effective in vivo gene delivery vectorIn situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration.Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy.Porcine adenovirus type 3 E1B large protein downregulates the induction of IL-8.
P2860
Q30226988-4F3052A4-A6D5-412F-9BFC-A124BD600B04Q33608746-C9ADB335-D4F0-48E2-ADCB-8CDE51435970Q33720616-541DEB1A-4C58-4F74-A7D2-DFA54DA40A18Q33727055-D05A46F7-0950-4126-B3CC-F2025C3BA040Q33730693-825ECF94-10E6-403E-B36B-10D6CFCB390AQ33985663-1FC282AD-E9DF-42EB-AA05-2CF45727BFE3Q34005560-F0763380-220E-4A05-91C9-F8FA55669B60Q34585554-A2D7EB8F-2565-413A-8085-EE42A3887741Q34599868-B652BCE5-63D5-4368-B8A1-CBD0E15C394EQ34600592-C4183BF3-ED77-4169-BC53-2F74DEB3250BQ34625994-024201F7-FD08-499C-A8AE-4E7345FE6812Q34648154-A92641E4-925E-4BDD-89A4-F12207EDCF62Q34701517-AC8F8291-6643-4854-85B5-84FE01076DD2Q35196230-76740F78-19BA-4B00-AA3D-5A90C514AD5EQ36014803-1F130622-9EEB-4B79-9B0C-1C16FC001AA9Q36315185-6D738D88-E839-448D-AE9E-B9CF95AEA660Q36463070-70D1A6B7-7C89-4486-918A-77E5392DF95DQ36873456-FA453D8D-BF11-4902-9611-F04B8C6F08BDQ36954135-5C8668AD-6D5E-4DEA-A04D-E32DAFF5955DQ37067254-FB65E854-16AD-4CED-9FC4-38542AA7B1E0Q37256524-5368613C-F166-42DA-8840-A5E0DF794FE6Q37495650-FCA2FE74-CDB5-43BD-9E3F-37D5A74A6274Q37508260-B64D2483-0CE4-4F83-ABCA-17C8512A14D1Q37631284-108A465E-E8B3-4E0F-806B-12BB083F4EBDQ39752604-CC885D52-B2B9-479B-808C-854CBC9D4778Q42722223-D567D74E-F271-408A-B9F6-A2D8BA59EB8C
P2860
Antivector and antitransgene host responses in gene therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antivector and antitransgene host responses in gene therapy.
@ast
Antivector and antitransgene host responses in gene therapy.
@en
Antivector and antitransgene host responses in gene therapy.
@nl
type
label
Antivector and antitransgene host responses in gene therapy.
@ast
Antivector and antitransgene host responses in gene therapy.
@en
Antivector and antitransgene host responses in gene therapy.
@nl
prefLabel
Antivector and antitransgene host responses in gene therapy.
@ast
Antivector and antitransgene host responses in gene therapy.
@en
Antivector and antitransgene host responses in gene therapy.
@nl
P2093
P1476
Antivector and antitransgene host responses in gene therapy
@en
P2093
Crystal RG
Hackett NR
Kaminsky SM
P304
P577
2000-08-01T00:00:00Z